Skip to main content

Lower Limb Spasticity News (Page 2)

Ipsen Announces FDA approval of Dysport (abobotulinumtoxinA) for the Treatment of Lower Limb Spasticity in Adults

June 16, 2017 – Ipsen (Euronext: IPN; ADR: IPSEY) (Ipsen) today announced that the U.S. Food and Drug Administration (FDA) has expanded the approved use of Dysport (abobotulinumtoxinA) for injection...

Ipsen Biopharmaceuticals, Inc. Announces FDA Approval of Dysport (abobotulinumtoxinA) for the Treatment of Lower Limb Spasticity in Pediatric Patients Aged Two and Older

BASKING RIDGE, N.J., Aug. 1, 2016 /PRNewswire/ – Ipsen Biopharmaceuticals, Inc., a subsidiary of Ipsen SA (Euronext: IPN; ADR: IPSEY) (Ipsen), today announced that the U.S. Food and Drug...

FDA Approves Botox (onabotulinumtoxinA) for the Treatment of Lower Limb Spasticity

DUBLIN, Jan. 22, 2016 /PRNewswire/ – Allergan plc (NYSE: AGN), a leading global pharmaceutical company today announced that the U.S. Food and Drug Administration (FDA) has approved Botox...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Related drug support groups

Botox